Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 29433850

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2018 Mar 24
First author
Kudo M

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2018 Mar 24;391(10126):1123-1124. doi: 10.1016/S0140-6736(18)30208-3.
    note
    Source null
    related pmid
    29433849
    relationship
    Comment in
  2. citation
    Nat Rev Gastroenterol Hepatol. 2018 Apr;15(4):190. doi: 10.1038/nrgastro.2018.20.
    note
    Source null
    related pmid
    29487423
    relationship
    Comment in
  3. citation
    Hepatobiliary Surg Nutr. 2018 Jun;7(3):221-224. doi: 10.21037/hbsn.2018.06.06.
    note
    Source null
    related pmid
    30046580
    relationship
    Comment in
  4. citation
    Hepatobiliary Surg Nutr. 2018 Dec;7(6):490-491. doi: 10.21037/hbsn.2018.08.06.
    note
    Source null
    related pmid
    30652097
    relationship
    Comment in

Authors and identifiers

  1. name
    Kudo M
    type
    Author
  2. name
    Finn RS
    type
    Author
  3. name
    Qin S
    type
    Author
  4. name
    Han KH
    type
    Author
  5. name
    Ikeda K
    type
    Author
  6. name
    Piscaglia F
    type
    Author
  7. name
    Baron A
    type
    Author
  8. name
    Park JW
    type
    Author
  9. name
    Han G
    type
    Author
  10. name
    Jassem J
    type
    Author
  11. name
    Blanc JF
    type
    Author
  12. name
    Vogel A
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Kudo M
    type
    Author
  2. name
    Finn RS
    type
    Author
  3. name
    Qin S
    type
    Author
  4. name
    Han KH
    type
    Author
  5. name
    Ikeda K
    type
    Author
  6. name
    Piscaglia F
    type
    Author
  7. name
    Baron A
    type
    Author
  8. name
    Park JW
    type
    Author
  9. name
    Han G
    type
    Author
  10. name
    Jassem J
    type
    Author
  11. name
    Blanc JF
    type
    Author
  12. name
    Vogel A
    type
    Author
bibliography ids
  1. nci-bib-0df262d41e50e03829a23b1e
book metadata
content sha256
8da77fee2b1624319987cc525df142c77a33fa3bebb85ad08a28a7bcba8d711c
document type
citation
dois
  1. 10.1016/S0140-6736(18)30207-1
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:29433850
immutable id
pubmed:29433850@8da77fee2b1624319987cc525df142c77a33fa3bebb85ad08a28a7bcba8d711c
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
10126
name
Lancet (London, England)
nlm unique id
2985213R
pages
1163-1173
volume
391
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2018 Mar 24;391(10126):1123-1124. doi: 10.1016/S0140-6736(18)30208-3.
    note
    Source null
    related pmid
    29433849
    relationship
    Comment in
  2. citation
    Nat Rev Gastroenterol Hepatol. 2018 Apr;15(4):190. doi: 10.1038/nrgastro.2018.20.
    note
    Source null
    related pmid
    29487423
    relationship
    Comment in
  3. citation
    Hepatobiliary Surg Nutr. 2018 Jun;7(3):221-224. doi: 10.21037/hbsn.2018.06.06.
    note
    Source null
    related pmid
    30046580
    relationship
    Comment in
  4. citation
    Hepatobiliary Surg Nutr. 2018 Dec;7(6):490-491. doi: 10.21037/hbsn.2018.08.06.
    note
    Source null
    related pmid
    30652097
    relationship
    Comment in
outcomes validated
false
pmid
29433850
provenance
batch id
ec9444d0f4cade22eb9f
provider
NCBI PubMed ESummary
record sha256
dbb2f3814b6aeb150e6ad662b611c84a0689bf69433f3d8af9aab0da63133d26
response sha256
6eef0d8cc09b77e73af656f6390cc734befb84fbc4c229b886e81e5d95bece31
retrieved at
2026-09-09T23:47:30.975610+00:00
publication date
display
2018 Mar 24
precision
day
year
2018
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
  7. Equivalence Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/29433850/
title
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.

Preserved source evidence · Not medical advice